Real-World Observations in Obstructive Hypertrophic Cardiomyopathy Patients Treated with Mavacamten: Evidence of Favorable Disease Modification.

Background: Mavacamten is commercially approved for use in symptomatic obstructive hypertrophic cardiomyopathy (oHCM) patients. This study evaluated its real-world impact on symptoms, echocardiographic changes, and the need for septal reduction therapy (SRT) in oHCM patients treated at a multi-hospital referral center.

Methods: We included 244 oHCM patients (mean age 64 years, 57% female, 21% with atrial fibrillation, 51% New York Heart Association [NYHA] Class III, 82% on beta-blockers) treated with mavacamten for ≥3 months (171 for ≥12 months).

Real-World Artificial Intelligence-Based Electrocardiographic Analysis to Diagnose Hypertrophic Cardiomyopathy.

Background: There is an emerging interest in artificial intelligence-enhanced 12-lead electrocardiogram (AI-ECG) in detection of hypertrophic cardiomyopathy (HCM).

Objectives: This study describes the initial real-world experience of using AI-ECG (Viz-HCM, developed using a convolutional neural network trained algorithm) in our center.

Methods: All patients undergoing 12-lead electrocardiograms at Cleveland Clinic, Cleveland, Ohio, between February 19, 2024, and November 1, 2024, were prospectively analyzed for potential HCM using AI-ECG.